… Piperacillin-tazobactam (TZP) is a combination of an … inhibitor and is frequently used for
nosocomial infections (3, 21). … for both piperacillin and tazobactam among hospitalized patients …

Cefoperazone-sulbactam (CS) and piperacillin-tazobactam (TZP) are used in the treatment
of Gram-negative nosocomial infections (NIs). We aimed to compare the effects of these two …

… aeruginosa is 64/4 mg/L for PIP/TAZ, the majority of hospital-acquired infection patients …
The results support the notion that nosocomial patients who have P. aeruginosa infection are …

… of piperacillin-tazobactam versus piperacillin–sulbactam against common nosocomial …
For Gram-positive bacteria, antimicrobial susceptibilities to the two piperacillin–β-lactamase …

… , and respiratory tract of patients with nosocomial infections in different parts of the
hospital … with nosocomial infections at Alzahra Hospital, were sensitive to piperacillin-tazobactam. …

… use of piperacillin–tazobactam in the treatment of infections … of tazobactam in the
piperacillin–tazobactam combination … -abdominal infections, gynecological infections, nosocomial …

… Nosocomial pneumonia (NP) accounts for approximately 15% of all nosocomial infections
… NP is the second most common nosocomial infection and is a leading cause of death in …

… Pneumonia is the second most common type of nosocomial infection (3, 14, 15, 18). It
represents 15 to 18% of nosocomial infections, translating into four to seven episodes/1,000 …

… Combination regimens of piperacillin/tazobactam plus an aminoglycoside are used to
treat … severe nosocomial (hospital-acquired) infections. In clinical trials, piperacillin/tazobactam …

… Nosocomial LRTI is now the second most common nosocomial infection following only
urinary tract infections … source and the setting; nosocomial pneumonia has been reported in …